Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has announced promising topline results from its Phase 1 study of tivoxavir marboxil, an investigational one-dose influenza treatment. Designed to inhibit the CAP-dependent …
Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil Read More